Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:40:46.886Z.
Calculation as of: 2026-10-06T19:40:46.886Z.
Quote observation: 2026-10-06T19:40:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 401df0919e13a39c0e4d05d537d83fb211652c6927e4412e931988a7f945bb4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Bullfrog AI Holdings, Inc. Common Stock
Market Cap
$12.24M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.43M
EBITDA Yield
N/A
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $12.24M | N/A | N/A | N/A | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.25M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.05M | N/A | 0.96% | 2.71% | 3.80% |
| Tempest Therapeutics, Inc. (TPST)vs › | $12.43M | N/A | 0.00% | 0.00% | 0.00% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.46M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.47M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.83M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.63M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.32M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute